200 related articles for article (PubMed ID: 18983237)
1. Combination therapy for malignant glioma based on PTEN status.
Gonzalez J; de Groot J
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1767-79. PubMed ID: 18983237
[TBL] [Abstract][Full Text] [Related]
2. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
3. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
[TBL] [Abstract][Full Text] [Related]
4. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
Chaudhuri S; Singh MK; Bhattacharya D; Datta A; Hazra I; Mondal S; Faruk Sk Md O; Ronsard L; Ghosh TK; Chaudhuri S
J Cell Physiol; 2018 Feb; 233(2):759-770. PubMed ID: 28608562
[TBL] [Abstract][Full Text] [Related]
5. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
6. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.
Abounader R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):235-45. PubMed ID: 19192961
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting for malignant gliomas (Review).
Kondo Y; Hollingsworth EF; Kondo S
Int J Oncol; 2004 May; 24(5):1101-9. PubMed ID: 15067331
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Targeted Therapy for Glioma.
Lin L; Cai J; Jiang C
Curr Med Chem; 2017; 24(13):1365-1381. PubMed ID: 28019637
[TBL] [Abstract][Full Text] [Related]
9. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
10. Targeted molecular therapy of malignant gliomas.
Kesari S; Ramakrishna N; Sauvageot C; Stiles CD; Wen PY
Curr Neurol Neurosci Rep; 2005 May; 5(3):186-97. PubMed ID: 15865884
[TBL] [Abstract][Full Text] [Related]
11. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
12. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
13. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapy for malignant glioma.
Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
[TBL] [Abstract][Full Text] [Related]
15. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors.
Castellino RC; Durden DL
Nat Clin Pract Neurol; 2007 Dec; 3(12):682-93. PubMed ID: 18046441
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
18. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
19. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Su JD; Mayo LD; Donner DB; Durden DL
Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
[TBL] [Abstract][Full Text] [Related]
20. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Coughlin CM; Johnston DS; Strahs A; Burczynski ME; Bacus S; Hill J; Feingold JM; Zacharchuk C; Berkenblit A
Breast Cancer Res Treat; 2010 Nov; 124(1):1-11. PubMed ID: 20803067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
